Research Analysts’ Recent Ratings Changes for Shire (SHPG)

Several analysts have recently updated their ratings and price targets for Shire (NASDAQ: SHPG):

  • 2/6/2018 – Shire was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “The sales of Mydayis did not meet Shire’s expectation while strong performance of Vyvanse, Cinryze and Elaprase continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past one year. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters.”
  • 2/5/2018 – Shire was given a new $192.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock. They wrote, “We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth.””
  • 2/5/2018 – Shire had its price target raised by analysts at Bank of America Corp from $236.00 to $237.00. They now have a “buy” rating on the stock.
  • 2/2/2018 – Shire was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 1/26/2018 – Shire was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/10/2018 – Shire was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/5/2018 – Shire was given a new $225.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 1/3/2018 – Shire was given a new $222.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 1/3/2018 – Shire had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 1/2/2018 – Shire was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “The sales of Mydayis did not meet Shire’s expectation while strong performance of Vyvanse, Cinryze and Elaprase continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past one year. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters.”
  • 12/31/2017 – Shire was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 12/27/2017 – Shire was given a new $222.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/20/2017 – Shire had its “hold” rating reaffirmed by analysts at Liberum Capital.

Shire PLC (NASDAQ:SHPG) traded up $1.20 on Monday, hitting $127.43. The stock had a trading volume of 2,068,700 shares, compared to its average volume of 1,507,348. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire PLC has a twelve month low of $123.73 and a twelve month high of $192.15. The firm has a market capitalization of $38,342.93, a PE ratio of 23.86, a P/E/G ratio of 0.68 and a beta of 1.41.

Shire (NASDAQ:SHPG) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.86 by ($0.49). Shire had a return on equity of 14.41% and a net margin of 10.95%. equities research analysts forecast that Shire PLC will post 15 earnings per share for the current fiscal year.

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply